Showing 56-60 of 61 :
OM1 Lupus Registry Reaches More Than 25,000 Patients Prospectively Followed With Deep Clinical And Lab Data

OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]

Artificial Intelligence for Real-World Evidence

Published on HealthEconomics.com on January 3, 2018   As artificial intelligence (AI) and Big Data are lauded for their potential uses in life sciences and healthcare, it is becoming difficult to differentiate between the myriad of terms and technologies and their real value in advancing real-world evidence (RWE).   In this article, we explore key AI[…]

Big Data Reveals 1 out of 6 ER Visits in Q2 2017 Opioid Related

BIG DATA REVEALS 1 OUT OF 6 ER VISITS IN Q2 2017 OPIOID RELATED OM1 launches a prototype for tracking the public health crisis in near real time BOSTON, November 27, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced it has[…]

Big Data Analyses of the New ACC/AHA Blood Pressure Guidelines

77% OF ADULT PATIENTS, SEEN BY HEALTHCARE PROVIDERS, NOW HAVE HIGH BLOOD PRESSURE OM1 releases big data analyses of impact of new blood pressure guidelines BOSTON, November 20, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced the release of big data[…]

Big Ideas for Big Data Analytics in Real-World Evidence

Published August 9  – by HealthEconomics.com Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Dr. Rich Gliklich, CEO of OM1, to discuss how big data analytics are changing the face of real world evidence (RWE). HealthEcoOM1logonomics.Com asked Dr. Gliklich to shares his views on major transformational changes in evidence development and how these will[…]